Conference reports

Increased risk of ART-related hepatotoxicity in HIV positive pregnant women

Darunavir pharmacokinetics in pregnancy and postpartum

BHIVA Autumn Conference, 9-10 October 2014, London

Good management of HIV positive pregnant women in UK – with some room for improvement

Southern African Clinicians Society Conference, 24-27 September 2014, Cape Town, South Africa

Efavirenz-associated gynaecomastia reported to the national HIV and TB healthcare workers hotline in South Africa

Infants start ART too late but improvement over time in Southern Africa

Treatment outcomes in HIV positive and negative people with drug resistant TB in Khayelitsha, Cape Town

Pregnancy a risk factor for poor antiretroviral treatment outcomes in South African adolescents

54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 5-9 
September 2014, Washington, DC

Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP

Switch from efavirenz to rilpivirine quells CNS toxicity, improves sleep

HIV persists in lung macrophages of people on suppressive ART

Only 10% of veterans with HCV or HCV/HIV in the US treated for HCV



20th International AIDS Conference, 20-25 July 2014, Melbourne

Update on baseline STIs in UK oral PrEP study (PROUD)

High prevalence of COPD at baseline in START study sub-study

Risk of CVD or type-2 diabetes according to change in BMI after starting ART

Rosuvastatin may be partially effective in moderating residual immune activation on ART

Reasons for loss to follow up in the Malawi Option B+ programme

20th International AIDS Conference, 20-25 July 2014, Melbourne

The loss of friends and colleagues from flight MH 17

Higher ART coverage is associated with lower HIV infection rates in a multi-country analysis

Pill A, Pill B: simplified second-line treatment for low-income countries

UNAIDS sets 90-90-90 target for 2020 to end AIDS by 2030

No difference in overall anaemia rate with reduced dose AZT

Open label oral PrEP at four doses a week: why zero infections does not equal 100% efficacy

Cure research at IAS 2014: TILDA measures the reservoir and romidepsin wakes it up

HIV and transgender issues at AIDS 2014

Transgender services and clinics: interviews at AIDS 2014 with JoAnne Keatley and Beatriz Grinsztejn

Publications launched at AIDS 2014

6th International Workshop on HIV Paediatrics, 18-19 July 2014, Melbourne

Update on paediatric antiretrovirals

Is d4T a viable option for children in low-income countries?

3TC or FTC monotherapy suboptimal as a bridging strategy for adolescents

Rationalising the paediatric antiretroviral formulary in Malawi

Time to first-line failure in the IeDEA cohort

Influence of early ART on antibody detection in children

8th International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource-Poor Settings (INTEREST), 5-6 May 2014, Lusaka, Zambia

Short-term safety of atazanavir/ritonavir-based second line treatment in Zambia

Pregnancy outcomes in Zambia

Uptake of ART is influenced by distance to the health facility in rural Zambia

Genotyping using dried blood spots in rural South African setting

49th Annual Meeting of the European Association for the Study of the Liver (EASL 2014), 9-13 April 2014, London

Activists protest the price of sofosbuvir: “So-Valdi, So-Expensive” – UK access already rationed

EASL 2014: summary of interferon-free HCV studies with new DAAs

WHO launch treatment guidelines for hepatitis C (2014)

3rd Joint Conference of BHIVA/BASHH, 1-4 April 2014, Liverpool

50% of UK seroconverters start ART within 1.4 years of infection: treating during primary infection should be a patient choice

PIVOT study: further analysis from five-year PI/r monotherapy strategy study

Sexually transmitted HCV in HIV positive and negative gay men

Annual HCV testing and use of core antigen to reduce costs and increase diagnosis during acute HCV

HIV positive attitudes to involvement as donors and recipients in organ transplant programmes

21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston

Pharmacokinetics of antiretrovirals in pregnancy

Better virologic outcomes with efavirenz vs lopinavir/ritonavir in pregnant women and no difference in risk of preterm birth

Once daily lopinavir/ritonavir not recommended for routine use in children and adolescents

Early antiretroviral treatment in infants

Hospitalisation among elite controllers

Catching up with pathogenesis and cure research from CROI 2014

21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston

No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up

PrEP injections every three months may protect against exposure from anal sex

ARV pipeline: doravirine, GSK-744 and BMS-068

Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study

Post navigation